Breaking News, Trials & Filings

FDA Grants FTD to Proteostasis Therapeutics

For their triple combination program for the treatment of cystic fibrosis

The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for Proteostasis Therapeutics’ triple combination program for the treatment of cystic fibrosis.    The proprietary triple combination includes a novel cystic fibrosis transmembrane conductance regulator (CFTR) amplifier, third generation corrector and potentiator, known as PTI-428, PTI-801 and PTI-808, respectively. Proteostasis announced in January that the protocol for its triple combination clinical study, ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters